By Choo Zheng, Fei Han, Chelsea Chen, Rachel Kroe-Barrett, and Andrew Nixon
Protein A purification is part of the standard workflow in downstream processing of therapeutic monoclonal antibodies. Traditional antibody purification processes can be slow due to long sample loading time. Also, additional steps may be required to concentrate the purified material. A new technology couples Protein A ligands to a proprietary membrane matrix, offering the potential for high dynamic binding capacity with a shorter lead time.
In this application note we assess the DBC10 and residence time of the membrane-based GORE Protein Capture Device as compared with an agarose-based Protein A column.
Membrane-based technology such as the GORE Protein Capture Device with Protein A offers the advantages of high dynamic binding capacity and short residence time. Together with high titers, the GORE column can reduce overall process time and may help increase yields in monoclonal antibody purification by eliminating the need for additional downstream concentration steps.